Rezolute, Inc. quarterly report, Q3 FY2021

Rezolute, Inc. — Form 10-Q Summary

Reporting period: Quarter and nine months ended March 31, 2021 (Rezolute fiscal third quarter 2021). The supplied “2020 Q3” label does not match the filing period. All dollar amounts below are in U.S. dollars.

Business context

Rezolute is a clinical-stage biopharmaceutical company with no commercial products or revenue. Its lead candidate, RZ358, is in Phase 2b development for congenital hyperinsulinism (CHI); RZ402 is in Phase 1 development for diabetic macular edema (DME).

Key financial metrics

At March 31, 2021, cash and cash equivalents were $32.0 million, working capital was $28.6 million, total assets were $32.9 million, total liabilities were $3.8 million, and accumulated deficit was $161.6 million. Nine-month operating cash use was $15.2 million; investing cash flow was zero. The filing reports no revenue, so commercial margins are not applicable.

Changes versus comparable periods

• Quarterly operating expenses rose 8% from $5.1 million; net loss narrowed from $5.0 million, helped by a $1.8 million non-cash gain on remeasurement of a derivative liability.
• Nine-month operating expenses declined 4% from $17.0 million and net loss narrowed from $16.8 million. R&D expense fell 12%, while G&A expense increased 14%.
• Quarterly clinical trial costs increased to $1.5 million from $0.6 million, primarily due to RZ402 Phase 1 enrollment. Nine-month R&D was lower amid COVID-related curtailment and completion of the AB101 Phase 1 study; it included a $1.0 million RZ402 licensing milestone.
• Operating cash use improved from $20.1 million to $15.2 million for the nine-month period. Cash increased from $10.0 million at June 30, 2020, principally due to the October 2020 equity financing.

Funding, outlook, and risks

• The October 2020 private placement raised $41.0 million gross and approximately $37.5 million net. The company reported $32.0 million cash at quarter-end and said cash plus $15.0 million borrowed in April 2021 should fund currently planned activities through at least June 30, 2022.
• In April 2021, the company entered a secured loan facility of up to $30.0 million. It received $15.0 million; the remaining $15.0 million depends on financing and clinical milestones. The initial rate was 8.87%, with interest-only payments permitted through May 2023. The loan is secured by substantially all assets, including intellectual property, and requires at least $5.0 million in restricted cash beginning no later than December 31, 2021.
• Management expected the RIZE Phase 2b RZ358 study to complete in the second half of calendar 2021, subject to COVID-19 conditions. RZ402 Phase 1a topline results announced in May 2021 were described as positive; Phase 1b was expected to start in Q3 2021, with completion targeted by Q1 2022. These are forward-looking expectations, not assured outcomes.
• COVID-19 could delay enrollment, site initiation, trial activities, or supply delivery, increase costs, and constrain access to financing. Management said productivity and reported financial results had not been materially affected to date, but future impacts remained uncertain.
• A February 2021 charter correction reduced authorized common shares to 10.0 million, below shares outstanding plus shares reserved for options and warrants. This created a $1.8 million derivative liability at March 31 and prevented ATM sales under the $50.0 million equity distribution agreement at that date. Stockholder approval to increase authorized shares was scheduled for May 26, 2021; approval and any subsequent financing were not assured.
• Management identified two material weaknesses in internal control over financial reporting: inadequate segregation of duties and ineffective treasury controls over authorized shares and share-issuance commitments. The company also disclosed Nasdaq board and audit-committee independence noncompliance and the risk of delisting if it did not regain compliance.
• Potential license commitments include up to $37.0 million in Xoma clinical/regulatory milestones and up to $46.5 million in ActiveSite milestones, plus applicable royalties. The company reported no pending or threatened material lawsuits.

Important facts for investors to verify

1. Whether stockholders approved the proposed authorized-share increase and reincorporation, and whether the share deficiency and related derivative liability were eliminated.
2. RZ358 and RZ402 trial progress, results, timelines, and any COVID-related delays or cost changes.
3. Cash burn and runway after the April loan, including restrictions, interest, fees, collateral, covenants, and conditions for later tranches.
4. Nasdaq listing compliance and remediation of both disclosed internal-control material weaknesses.
5. Potential dilution from outstanding options and warrants, any ATM issuance, and future financing needs beyond management’s stated runway.